No abstract

No abstract

Background: Cerebral venous sinus thrombosis (CVST) often presents with acute seizures, and recurrent seizures may also be seen in the long term in some patients. The purpose of this retrospective study was to investigate the frequency and type of acute seizures and to define the risk factors. Methods: Sixty-two patients diagnosed with CVST between September 2007 and October 2018 were retrospectively evaluated for the occurrence of acute seizures. Seizures which developed as a presenting symptom or occurred within 2 weeks of diagnosis were defined as acute seizures. Demographic, clinical, and radiologic characteristics were compared between patients with or without acute seizures. Results: Twenty (32.3%) of the 62 CVST patients had acute seizures. Univariate analysis revealed a significant association between acute seizures and aphasia (P=0.03), motor deficit (P<0.001), sensory deficit (P=0.018), severe (≥3) modified Rankin Scale scores on admission (P=0.017), sagittal sinus thrombosis (P=0.037), cortical vein thrombosis (P<0.001), supratentorial lesions (P<0.001), and hemorrhagic lesions (P<0.001). Multivariate regression analysis identified supratentorial lesions (P=0.015, odds ratio: 9.131, 95% confidence interval: 1.525-54.687) and cortical vein thrombosis (P=0.034, odds ratio: 5.802, 95% confidence interval: 1.146-29.371) as independent factors for acute seizures. Although 25% of patients with acute seizures had recurrent seizures during hospitalization, only 2.6% of the 38 patients with long-term follow-up had recurrent seizures. Conclusions: Approximately one third of patients with CVST had acute seizures. Cortical vein thrombosis, supratentorial, and especially hemorrhagic lesions were the most significant risk factors associated with acute seizures. Although seizure recurrence may occur early in the course, long-term recurrence is rare in CVST.

Objective: This was a retrospective study of the hospital database from April 2020 to January 2021 to reveal the rate of Helicobacter pylori infection among Dementia patients who underwent percutaneous endoscopic gastrostomy (PEG) procedure. Other aim of this study is examine the effect of a single dose (two grams) intravenous ceftriaxone plus pantoprazole (40 mg) before PEG  procedure on H.pylori infection in Dementia patients. Material and Methods: This is a retrospective observational study of hospital database from April 2020 to January 2021 examining the effect of using a single dose (two grams) of intravenous ceftriaxone plus pantoprazole (40 mg) on H.pylori infection in Dementia patients.  A total of 77 patients, (43 (64%) of them were female) with Dementia were included whose 67 had previously been diagnosed as Dementia and underwent PEG procedure. The control group (67 subjects; 40 of them were female and the mean age was 75.8±11 years) was selected from age and gender-matched dyspeptic subjects who underwent endoscopy Results: While the mean age in the Dementia group was 75.8±12 years, the mean age of the control group was 77.8 ±11 years (p=0.054). There were also no gender differences between groups (p=0.594). While the mean levels of serum albumin, urea, creatinine, hemoglobin were significantly lower than control subjects (All p values were below 0.001), the mean of serum ferritin level was higher than control subjects (p<0.01). The presence of H.pylori on gastric biopsy specimens was significantly lower in the Dementia group compared to control subjects (19.4% versus 55.2%). Conclusion: Our study indicated that the rate of H.pylori infection was lower than estimated and using single-dose intravenous ceftriaxone at a dose of 2 grams could be beneficial for treating H.pylori infection in patients with Dementia who faced difficulties related to lack of swallowing many drugs against H.pylori infection.

IntroductionAlzheimer’s disease (AD) is a neurodegenerative disorder characterized by a progressive decline in memory and cognitive abilities. The monocyte/HDL-C ratio (MHR) has emerged as a new marker of inflammation in recent years. The purpose of this research was to examine MHR alterations in AD and to assess its feasibility as a straightforward and easily computable biomarker for evaluating the severity of the disease.Material and methodsA retrospective case-control study was conducted with 101 patients with AD and 81 age and sex-matched controls from the hospital records. AD was diagnosed according to the National Institute of Neurological and Communicative Disorders and Stroke/Alzheimer’s Disease and Related Disorders Association (NINCDS-ADRDA) criteria. The hospital’s electronic patient record data between September 2021 and April 2022 were screened.ResultsIndividuals diagnosed as having AD were classified into three subgroups based on the progression of the disease, mild, moderate, and severe. MHR was higher in the moderate and severe dementia subgroups compared with the controls according to subgroup analysis (P=0.013). An increase in MHR was found in patients with AD. The multivariate logistic regression analysis model revealed that a one-unit increase in MHR resulted in a 1.081 times increase in the risk of AD (OR: 1.081, 95% CI: [1.005-1.162]; P= 0.035).ConclusionsHigh MHR values could not be used as a diagnostic test for AD. Instead, because it negatively correlates with MMSE, it could be a good index reflecting the increased AD risk and disease severity.